BioMarin Pharmaceutical Inc. (BMRN)
BMRN trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$54.38
-1.82% on the day
Market cap
$10.5B
Large cap
Revenue · 2025
$3.2B
+12.9% on 2024
Net income · 2025
$348.9M
10.8% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | BMRN on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 1999 |
| SEC CIK | 0001048477 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $3.2B |
| Net income | $348.9M |
| Operating income | $409.5M |
| Net margin | 10.8% |
| Operating margin | 12.7% |
| Revenue growth | +12.9% |
| Cash | $1.3B |
| Total assets | $7.6B |
| P/E (computed) | 30.2× |
| P/S (computed) | 3.3× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2017-08-09 |
| Latest annual report | 10-K | 2026-02-26 |
| Latest quarterly / interim | 10-Q | 2026-08-06 |
| Latest current report | 8-K | 2026-10-06 |
| Latest proxy | DEFA14A | 2026-04-21 |
Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -0.2% |
| 1 month | -14.5% |
| 3 months | -8.2% |
| Year to date | -7.3% |
| 1 year | +5.0% |
| From 52-week high | -21.6% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| MDGL | Madrigal Pharmaceuticals Inc. | $452.12 | -3.22% | $10.4B |
| RDY | Dr. Reddy's Laboratories Ltd | $12.77 | -0.39% | $10.7B |
| ELAN | Elanco Animal Health Incorporated | $22.41 | -0.67% | $11.2B |
| PTGX | Protagonist Therapeutics Inc. | $138.49 | -4.41% | $9.0B |
| BBIO | BridgeBio Pharma Inc. | $63.30 | -3.73% | $12.4B |
| SMMT | Summit Therapeutics Inc. Common Stock | $15.52 | -9.40% | $12.4B |
| CORT | Corcept Therapeutics Incorporated | $117.80 | -2.80% | $12.7B |
| CYTK | Cytokinetics Incorporated | $61.62 | -1.86% | $8.6B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier